VivoSim Labs, Inc. (VIVS) - Total Liabilities
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has total liabilities worth $2.52 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VivoSim Labs, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
VivoSim Labs, Inc. - Total Liabilities Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
VivoSim Labs, Inc. Competitors by Total Liabilities
The table below lists competitors of VivoSim Labs, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Insplorion AB
ST:INSP
|
Sweden | Skr3.60 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €12.65 Million |
|
Black Spruce Exploration Inc.
V:BARK
|
Canada | CA$2.83 Million |
|
Centaurus Energy Inc
V:CTA
|
Canada | CA$5.59 Million |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
Indonesia | Rp569.64 Billion |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
Germany | €35.06 Million |
|
The Alumasc Group plc
LSE:ALU
|
UK | GBX45.48 Million |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
USA | $121.13 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down VivoSim Labs, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of VivoSim Labs, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VivoSim Labs, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VivoSim Labs, Inc. (2011–2025)
The table below shows the annual total liabilities of VivoSim Labs, Inc. from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $4.16 Million | +51.31% |
| 2024-03-31 | $2.75 Million | -44.86% |
| 2023-03-31 | $4.98 Million | +61.45% |
| 2022-03-31 | $3.09 Million | +328.16% |
| 2021-03-31 | $721.00K | -60.17% |
| 2020-03-31 | $1.81 Million | -58.15% |
| 2019-03-31 | $4.33 Million | -17.48% |
| 2018-03-31 | $5.24 Million | -23.13% |
| 2017-03-31 | $6.82 Million | +26.38% |
| 2016-03-31 | $5.39 Million | +12.56% |
| 2015-03-31 | $4.79 Million | +152.00% |
| 2014-03-31 | $1.90 Million | -91.37% |
| 2013-03-31 | $22.05 Million | +206147.66% |
| 2011-03-31 | $10.69K | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more